Actually, the animal results in tox studies establish the human reactive ranges that can be anticipated from results in mice, rats and dogs. Humans should fall somewhere in the middle of the range for MTD (mice highest MTD and dogs lowest MTD). I think DF and BI expect high efficacy well in the middle of the two species values. That's why the protocol has a initial dose well above the usual, and very rapid dose escalation in the first 3 or 4 cohorts.